: iStockAnalyst.com Symbols Feed

Bullish Picks for Next Week

Sat, 01 Aug 2009 16:59:14 GMT

Taking a look at stock market action last week, we see price consolidating after breaking to new highs. Stocks are being bought even after rather poor earnings reports, and meanwhile there are a good number of stocks reporting legitimately positive quarters. Money is flowing into equities, and traders have a large number of earnings winners from which to choose. Looking at the SPY chart, price made a major move to new highs on 7/23, and then broke out again on 7/30. The last two days of the week saw some end-of-day weakness, which provides some reason for short-term caution. In any case, this is a bullish chart. [More...]

Spectrum Pharma (NASDAQ:SPPI): Undervalued Based On Late-Stage Pipeline

Fri, 19 Jun 2009 16:45:08 GMT

With two potential approvals coming up in the next 120 days, Spectrum Pharmaceuticals (Nasdaq: SPPI) still remains a hidden gem. Investor's Business Daily bases its rankings on the relationship that one company has with other companies within the same industry. In my June 12 article, I indicated the company could likely generate $280 million in annual revenue within the next 12-18 months upon approval of both the company's cancer drugs Zevalin and Fusilev. The table below is a lis (...)[More...]

BioMedReports FDA Calendar: 19 Hot Summer Trades

Wed, 17 Jun 2009 12:13:04 GMT

Below is a sample of entries from the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The companies outlined below have expected FDA new drug product decisions or clinical trial results expected over the next three months of summer. The list also includes some Extreme Trades of companies with market caps below $250 million that have pending clinical trial results or FDA decisions that could have a major stock price impact. Rigel Pharma (NASDAQ:RIGL): On 5/5/09, (...)[More...]

FDA, Clinical Trial Updates: MAPP, CYTK, and HEB Post Big Gains

Wed, 27 May 2009 12:26:35 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

FDA, Clinical Trial Updates: WPI, UTHR, AUXL, DNDN

Wed, 29 Apr 2009 14:55:11 GMT

Biotech Churns Out Big Returns In Bull And Bear Markets

Mon, 06 Apr 2009 16:41:18 GMT

Editor’s Note: Marc Lichtenfeld is the Director of Research of Access Research Group and a Senior Analyst for the Xcelerated Profits Report. As investors begin to look more and more toward... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Pharmaceuticals Industry

Fri, 21 Nov 2008 20:17:00 GMT

Names that were previously viewed as safe and stable investments, large-cap pharmaceuticals, are now trading at levels not seen since 2002.? And, for some such as Pfizer, Inc. (PFE) and Eli Lilly & Co. (LLY), these are prices not seen since the past decade. This is clearly a sell-first, ask questions later market. After all, believing that patients are going to stop taking Bristol-Myers Squibb Co. (BMY) blood-thinner Plavix or Pfizer's anti-cholesterol agent Lipitor because of the credit crunch is the epitome of irrational anxiety. [More...]

United Therapeutics (NASDAQ:UTHR) : JP Morgan defending

Mon, 17 Nov 2008 12:40:00 GMT

JP Morgan is out defending United Therapeutics (NASDAQ:UTHR) after the phase III FREEDOM-C trial did not meet the primary endpoint of improvement in exercise capacity, as measured by the 6 minute walk distance (6MWD) in PAH patients receiving oral Remodulin in combination with Tracleer or Revatio over those receiving Tracleer/Revatio alone. Firm recalls that the FREEDOM-C protocol was amended to allow dose titration with smaller steps through the introduction of 0.5mg and 0.25mg doses, it is possible that together with a positive FREEDOM-M trial (which has a lower bar of needing to beat only placebo) and the new FREEDOM-DR study with all patients having a easier dose titration, oral Remodulin could still achieve regulatory and commercial success. United’s conf call is at 9 am (800 603 1777 US) and JPM is hosting a conference call today at 11am ET with[More...]

Analyst Comments: United Thera, Genta, Visteon, Watsco, Autonation, National Semi, Saks, Lehman, Joy Global, Nuvelo, 3D Systems, Suntech Power, Dassault, Cell Therapeutics, Analog Devices, Energy Transfer, General Growth

Wed, 20 Aug 2008 19:58:00 GMT

Although the current business fundamentals at United Therapeutics Corp. (UTHR) are solid, we are seeing several potential hiccups coming in the next year. With the stock up 65% over the past twelve months and currently trading at 50x our 2008 EPS estimate[More...]

Periodicals Wrap-Up for Tuesday, August 12th

Tue, 12 Aug 2008 14:36:00 GMT

Posted By Optiondragon for myhappytrading.com- the best social network for traders and investors.[More...]

The Daily Record News Briefs: March 17, 2009

Tue, 17 Mar 2009 05:50:00 GMT

Former dean Cleghorn dies
Cleghorn was dean of the journalism school from 1981 to 2000 and had taught courses in commentary and editorial writing until December.
He was instrumental in bringing the national monthly magazine American Journalism Review (then Washington Journalism Review) to the college in 1987, and has since served as president, and then publisher of AJR.

: iStockAnalyst.com Symbols Feed

Bullish Picks for Next Week

Spectrum Pharma (NASDAQ:SPPI): Undervalued Based On Late-Stage Pipeline

BioMedReports FDA Calendar: 19 Hot Summer Trades

FDA, Clinical Trial Updates: MAPP, CYTK, and HEB Post Big Gains

FDA, Clinical Trial Updates: WPI, UTHR, AUXL, DNDN

Biotech Churns Out Big Returns In Bull And Bear Markets

Pharmaceuticals Industry

United Therapeutics (NASDAQ:UTHR) : JP Morgan defending

Analyst Comments: United Thera, Genta, Visteon, Watsco, Autonation, National Semi, Saks, Lehman, Joy Global, Nuvelo, 3D Systems, Suntech Power, Dassault, Cell Therapeutics, Analog Devices, Energy Transfer, General Growth

Periodicals Wrap-Up for Tuesday, August 12th

The Daily Record News Briefs: March 17, 2009

Critics Say Stock Option Exchanges Unfair

Licensing Executives Society Announces 2009 Deals of Distinction Awards

United Therapeutics Corporation Reports Second Quarter 2009 Financial Results

FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension

United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009

United Therapeutics Corporation (UTHR) Chairman and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension

United Therapeutics Reports First Quarter 2009 Financial Results

Richard Giltner Joins United Therapeutics Board of Directors

U.S. Food and Drug Administration Extends Action Date for Inhaled Treprostinil (Tyvaso) New Drug Application by Three Months

Form 4 MAHON PAUL A For: Oct 15 (10K)

Form 4 JEFFS ROGER For: Oct 15 (10K)

Form 4 MAHON PAUL A For: Oct 01 (10K)

Form 4 JEFFS ROGER For: Oct 01 (10K)

Form 4 PATUSKY CHRISTOPHER For: Oct 01 (10K)

Form 4 CAUSEY CHRISTOPHER For: Oct 01 (10K)

Form 4 MAHON PAUL A For: Sep 24 (10K)

Form 4 CAUSEY CHRISTOPHER For: Sep 23 (10K)

Form 4 PATUSKY CHRISTOPHER For: Sep 03 (10K)

Form 4 MAHON PAUL A For: Sep 03 (10K)